The Company is providing guidance for 2025 for the first time, including: Sales are expected to grow by more than 50% in 2025, driven by further market share increases in the TriNav system, the commercial launch of the TriNav LV system, and the TriNav target market expansion driven by the DELIVER program. Operating expenses are expected to decline greater than 20% in 2025 due to reductions in R&D associated with completing the PERIO Phase 1 trials and reductions in G&A expenses due to the non-recurrence of certain costs related to becoming a public Company. The Company expects to achieve positive full-year EBITDA and positive cash flow in the second half of the year.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TLSI Earnings this Week: How Will it Perform?
- Pinterest, Cisco upgraded: Wall Street’s top analyst calls
- TriSalus Life Sciences teams with Geo-Med to expand TriNav availability to VA
- TriSalus Life Sciences initiated with a Buy at Roth MKM
- TriSalus Life Sciences files to sell 10.59M shares of common stock for holders